trelagliptin

02/26/2018 - "Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study."
03/01/2018 - "Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study."
12/01/2017 - "Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol."
02/01/2014 - "In this study, we assessed the efficacy and safety of SYR-472 in patients with type 2 diabetes. "
02/01/2014 - "SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial."

09/01/2016 - "We evaluated long-term safety and efficacy of trelagliptin in Japanese patients with type 2 diabetes mellitus. "
09/01/2016 - "Trelagliptin is a novel once-weekly oral dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus that was first approved in Japan. "
09/01/2016 - "Once-weekly oral trelagliptin provides well-tolerated long-term safety and efficacy in both monotherapy and combination therapies in Japanese patients with type 2 diabetes mellitus."
03/01/2020 - "To investigate the efficacy and safety of trelagliptin 25 mg in patients with type 2 diabetes mellitus with severe renal impairment or end-stage renal disease. "
09/01/2016 - "Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study."

04/01/2021 - "Treatment with trelagliptin exhibited an improvement in insulin resistance. "
05/01/2020 - "In this study, the effect of trelagliptin succinate in improving insulin resistance was investigated. "
05/01/2020 - "In conclusion, our study suggested that trelagliptin succinate improved insulin resistance in adipocytes via regulation of PI-3K/AKT/GLUT4 insulin signaling pathway."
05/01/2020 - "Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes."
05/01/2020 - "Trelagliptin inhibits the enzyme dipeptidyl-4 (DPP-4) to treat type 2 diabetes and it may possess the potential to improve insulin resistance. "

12/01/2015 - "52-week monotherapy and add-on therapy of trelagliptin also improved HbA1c levels without body weight gain and severe hypoglycemia. "
11/01/2019 - "Once-weekly trelagliptin and once-daily alogliptin improved glycemic control and reduced GV without inducing hypoglycemia. "

04/01/2021 - "The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice."
04/01/2021 - "In this study, we aimed to investigate the roles of trelagliptin in the development of NAFLD in a mouse model. "
04/01/2021 - "These findings suggest that trelagliptin might become a promising therapeutic agent for the treatment of NAFLD."
04/01/2021 - "However, the pharmacological function of trelagliptin in NAFLD has not been previously reported. "
04/01/2021 - "In addition, trelagliptin ameliorated oxidative stress in the liver of NAFLD mice by reducing malondialdehyde and increasing the levels of reduced glutathione and superoxide dismutase activity. "